Colorectal cancer (CRC) is a common malignancy worldwide. In CRC patients, metastases
are the main cause of cancer-related mortality. In a group of metastatic CRC patients, the …

The response to first-line therapy is a primary determinant of outcome in patients with
metastatic colorectal cancer (mCRC), for three main reasons: effective upfront therapy …

Importance The past 2 decades have witnessed progress in the management of metastatic
colorectal cancer (mCRC) with more effective agents and better surgical, medical, and …

Several parameters for predicting survival in patients with colorectal cancer have been
identified, including the performance status, age, gender and tumor-node-metastasis (TNM) …

Aim: To explore the prognostic value of extended mutational profiling for metastatic
colorectal cancer (mCRC). Materials & methods: We retrospectively reviewed survival …

Aims Triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan is a standard
therapy for metastatic colorectal cancer (CRC). Single nucleotide polymorphisms (SNPs) in …

Rectal cancer, along with colon cancer, is the second leading cause of cancer-related
deaths in the US Up to a quarter of patients have metastatic disease at diagnosis and 40 …

Background Multidrug regimens are active against advanced colorectal cancer (ACRC).
However, the increased toxicity requires the use of biomarkers to select the patients who will …

The past 30 years have seen the introduction of a number of cancer therapies with the aim of
restricting the growth and spread of primary and metastatic tumours. A shared commonality …

Background The effectiveness of reintroducing oxaliplatin in patients with metastatic
colorectal cancer refractory to standard chemotherapy has not been verified. We performed …